PRNewsWire
19 Feb 2026, 19:47 UTC · 30w ago
Verdict
Headline takes no side. We score RGNX −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA placed a clinical hold on REGENXBIO's RGX-111 gene therapy following a case of neoplasm (CNS tumor) in a Phase I/II study participant.
More negative than 99% of claims this week
The FDA also placed a clinical hold on RGX-121 for Hunter Syndrome due to shared risks and product similarities with RGX-111.
So whatThis extends the regulatory risk across multiple pipeline assets, compounding the potential loss of future revenue streams.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 99% of claims this week
A federal securities class action lawsuit has been filed against REGENXBIO alleging false or misleading statements regarding the safety and efficacy of RGX-111.
More negative than 87% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company faces FDA clinical holds on two gene therapy trials and is the target of a federal securities class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
34m ago
−5.1%
Price agrees with the score
$7.50 vs $7.90 close before publication (Feb 18) · not market-adjusted
RGNX chart →
